Lewis talks with Dr. Rahul Ballal, CEO at Imara Inc, a biopharmaceutical company.

Imara develops novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, and is currently developing IMR-687, a highly selective, potent small molecule inhibitor of PDE9, to treat patients with sickle cell disease. In this episode Rahul gives us insights on sickle cell disease and other hemoglobinopathies.

*This episode was recorded live on google hangouts.

Show notes:

website: https://www.imara.com/

-------------------------------------------------------------------------------­-----------------

This episode is supported by Audible:

Start your 30 day free trail today! using the following link: bit.ly/2YVdZJU

- Auto-renews at £7.99/month after 30 days

- 1 book monthly membership

- Cancel anytime

Take your pick from the world’s largest selection of audiobooks including best sellers, latest releases, sci-fi, fantasy and more.

Disclaimer:

If you sign up using our link, we make a small percentage and you help to support our podcast for which we are truly grateful. This doesn't affect our opinions.